{"preliminary_commentary":{"by_channel":{"x_thread":31,"podcast":4,"youtube":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02912949\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["zenocutuzumab"]],"indication":"solid tumors harboring NRG1 fusion","name":"eNRGy","nct_id":"NCT02912949","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=enrgy-nct02912949. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.","label":"Part 2 Pancreatic adenocarcinoma harboring NRG1 fusion","type":"EXPERIMENTAL"},{"description":"Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.","label":"Part 2 NSCLC cancer harboring NRG1 fusion","type":"EXPERIMENTAL"},{"description":"Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.","label":"Part 2 Solid tumour (basket) harboring NRG1 fusion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Solid Tumours Harboring NRG1 Fusion","NSCLC Harboring NRG1 Fusion","Pancreatic Cancer Harboring NRG1 Fusion","NRG1 Fusion"],"enrollment":{"count":250,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"zenocutuzumab (MCLA-128)","otherNames":["bispecific","MCLA-128"],"type":"DRUG"}],"last_update":"2025-04-29","lead_sponsor":"Partner Therapeutics, Inc.","official_title":"A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective overall response rate (ORR) as per local investigator's assessment","timeFrame":"36 months"},{"measure":"Duration of response per RECIST v1.1 as per local Investigator's assessment.","timeFrame":"36 Months"}],"references":[{"citation":"Cleary JM, Springfeld C, Arnold D, Hollebecque A, Gbolahan O, Nagasaka M, Siena S, Opdam F, Sunakawa Y, Cassier PA, Trikha G, Gort EH, Florou V, Greil R, La Porte PF, Gandhi PJ, Garner F, Wasserman E, Adeyemi S, Schram AM. Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial. J Clin Oncol. 2026 Oct 20;44(30):2908-2918. doi: 10.1200/JCO-25-03128. Epub 2026 Jul 1.","pmid":"42385125","type":"DERIVED"},{"citation":"Schram AM, Goto K, Kim DW, Macarulla T, Hollebecque A, O'Reilly EM, Ou SI, Rodon J, Rha SY, Nishino K, Duruisseaux M, Park JO, Neuzillet C, Liu SV, Weinberg BA, Cleary JM, Calvo E, Umemoto K, Nagasaka M, Springfeld C, Bekaii-Saab T, O'Kane GM, Opdam F, Reiss KA, Joe AK, Wasserman E, Stalbovskaya V, Ford J, Adeyemi S, Jain L, Jauhari S, Drilon A; eNRGy Investigators. Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer. N Engl J Med. 2025 Feb 6;392(6):566-576. doi: 10.1056/NEJMoa2405008.","pmid":"39908431","type":"DERIVED"},{"citation":"Kim DW, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha SY, Duruisseaux M, Liu SV, Al Hallak MN, Umemoto K, Wesseler C, Cleary JM, Springfeld C, Neuzillet C, Joe A, Jauhari S, Ford J, Goto K. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol. 2024;20(16):1057-1067. doi: 10.2217/fon-2023-0824. Epub 2024 Feb 13.","pmid":"38348690","type":"DERIVED"}],"start_date":{"date":"2015-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","url":"https://clinicaltrials.gov/study/NCT02912949"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/enrgy-nct02912949"}